Related Experiment Videos
Gene-gene interaction affects coronary artery disease risk
Maria Isabel Mendonça1, R Palma Dos Reis, A Isabel Freitas
1Unidade de Investigção, Hospital Central do Funchal, Funchal, Portugal. dep.card@srs.pt
Summary
Coronary artery disease (CAD) risk increases with combined gene polymorphisms, not those within the same gene. Associated polymorphisms in different genes, like ACE and PON1, significantly elevate CAD risk, offering insights into genetic predisposition.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Molecular Biology
Background:
- Previous studies on coronary artery disease (CAD) risk polymorphisms yielded contradictory results.
- Existing research often examined single nucleotide polymorphisms (SNPs) in isolation, neglecting their natural co-occurrence.
Purpose of the Study:
- To investigate the association between combined genetic polymorphisms and CAD risk.
- To determine if polymorphisms within the same gene or different genes influence CAD susceptibility.
Main Methods:
- Genotyping of ACE DD, ACE 8 CC, ACT 174MM, AGT 235TT, MTHFR 677TT, MTHFR 1298AA, PON1 192RR, and PON1 55MM in 298 CAD patients and 298 controls.
- Analysis of risk for polymorphisms within the same gene (e.g., ACE DD + ACE 8GG) and across different genes (e.g., ACE + AGT).
- Application of multiple logistic regression to identify independent CAD risk factors.
Main Results:
- Significant associations found for isolated polymorphisms: ACE DD (p < 0.0001), ACE 8 gg (p=0.023), and MTHFR 1298AA (p = 0.049).
- No additive or synergistic risk observed for polymorphisms within the same gene.
- Combined polymorphisms in different genes, such as ACE DD/ACE 8 GG with PON1 192RR, increased CAD risk fourfold.
- Independent predictors of CAD identified: smoking, family history, fibrinogen, diabetes, and combined polymorphisms (ACE DD/ACE 8 GG + MTHFR 1298AA; ACE DD/ACE 8 GG + PON1 192RR).
Conclusions:
- Polymorphisms within the same gene do not augment individual risk.
- Inter-gene polymorphism associations significantly elevate CAD risk compared to isolated polymorphisms.
- This study enhances understanding of cumulative genetic risk for CAD beyond single polymorphism analysis.
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...